S282 Poster Sessions / European Journal of Pain 13 (2009) S55–S285

1004

SEDATION OPTIONS FOR PAIN IN TERMINAL ILLNESS

P. Rojas1 *, M. Campos1, J. Campoy1, M.D. Gonzalez1, M. Gutierrez1,

M. Quesada2. 1Nursing Faculty, Murcia, Spain; 2FFIS, Murcia, Spain

Goal: To know the preferences of individuals as to how they wish to

be treated when faced with painful terminal illness and the factors

influencing these preferences.

Method: The study group is composed of 600 individuals of both

sexes picked at random to answer our validated questionnaire. A

descriptive statistical study of the variables was made, and the

Pearson test was applied to the data. The contrast of the averages

was made by means of t of Student.

Results: The average age is 41 years and there are 62% women and

38% men. Some 39.3% of the subjects have suffered pain previously

whilst 33.1% have lived with people with incapacitating pain. 78.4%

of respondents would prefer to be sedated despite it supposing

a shortening of life and this desire increases to 91.9% when the

patient is a family member. The women questioned have been

in contact with people with terminal disease to a greater extent

than the men (p < 0.05) and they prefer to be sedated despite it

supposing a shortening of life (p < 0.05). Men agree to be conscious

as long as possible even if this involved enduring pain (p < 0.05).

Conclusions: When faced with terminal disease with strong pain

the choice of our subject group is to be sedated although this

supposes a shortening of life. This option is preferred by the

majority when the patient is a member of family or by those

who have had previous contact with terminal patients.

1005

IMPACT ON DAILY LIFE IN PATIENTS WITH ASSUMED

NEUROPATHIC PAIN: A FOLLOW-UP STUDY

M.R. Saugbjerg1 *, T.S. Jensen2. 1Neurological Pain Clinic, Aarhus

University Hospital, DK-8000 Aarhus C, Denmark; 2Danish Pain

Research Center, Aarhus University Hospital, DK-8000 Aarhus C,

Denmark

Background and Aims: Patients are referred to the Neurological

Pain Clinic at Aarhus University Hospital because of neuropathic

pain. Only few data exist on the impact of pain on daily life years

after ending treatment at the clinic. This long term follow-up ques-

tionnaire study will examine quality of life and daily functioning

in chronic pain patients >3 years after treatment in a pain clinic.

Methods: As part of the assessment at their first visit, patients

are asked to complete a questionnaire at home. The questionnaire

contains demographic and social factors, pain assessment, previous

treatment, medication, sleep pattern, physical activity, and

expectations to treatment. In addition the patients are encouraged

to describe other problems related to their chronic pain. In 2008

all patients treated in the Pain Clinic in 2004 and 2005 received a

follow-up questionnaire with themes as changes in social condition,

new referrals to pain treatment/assessment, contact to GP, changes

in lifestyle, physical activity and the same listing of problems

related to having pain etc.

Results: In 2004 and 2005, 588 patients attended the Neuropathic

Pain Clinic, 97 had not completed the first questionnaire, 25 patients

had died and 62 had left the country or moved to an unknown

address. In total 429 patients were eligible for the study; of those

288 completed the second questionnaire (a response rate of 73%).

Conclusions: Data analysis is ongoing and results will be presented

at the congress

1006

LONG-TERM EFFICACY OF A MULTIMODAL TREATMENT

APPROACH FOR PATIENTS SUFFERING FROM CHRONIC PAIN

A. Schutze*, K. Grosse, U. Kaiser, M. Schiller, B. Konrad, P. Gerhardt,

U. Ettrich, R. Scharnagel, G. Gossrau, R. Sabatowski. Pain Clinic,

University of Dresden, Dresden, Germany

Background: Chronic pain (CP) is a prevalent medical problem,

often complicated by occupational or psychological cofactors.

Efficacy of multimodal treatment approaches (MT) could be

demonstrated for short- and intermediate-term outcome. However

there is only limited evidence of long-term efficacy. Our prospective

study analyses the 1 and 2 years catamnesis of CP-patients treated

with MT in a day clinic setting.

Methods: Standarized MT for 4 weeks initially followed by an

additional week 3 months later. Assessments of quality of life (SF-

36), pain (NRS), pain disability (PDI), anxiety/depression (HADS-D)

and coping strategies (CSQ) at the beginning of the treatment (T1),

after 1 (T2), 3 (T3), 6 (T4), 12 (T5) and 24 (T6) months. Only

the data of the long-term follow-up (T5, T6) will be presented. A

p≤0.05 was regarded as statistically significant. Effect sizes (ES)

were calculated.

Results: Questionnaires of 148 patients (mean age 51; treatment

period 2006–2007) and of 58 patients were available for T5 and T6.

All parameters tested revealed a statistical significant improvement

(T0 vs. T5/6). In the CSQ the most remarkably improvement

was achieved in catastrophizing (T1-T5: p < 0.001, ES 0.65; T1-T6:

p < 0.001, ES 0.61). Average pain intensity scores decreased signifi-

cantly (T1-T5: p < 0.001, ES 0.71; T1-T6: p =0.003, ES 0.58) as well.

Conclusions: The results suggest a long-term benefit, even two

years after MT, in patients suffering from CP.

1007

ONE YEAR CATAMNESIS AFTER MULTIMODAL TREATMENT OF

PATIENTS SUFFERING FROM CHRONIC HEADACHE

A. Schutze*, K. Grosse, G. Gossrau, M. Schiller, B. Konrad,

R. Scharnagel, U. Ettrich, P. Gerhardt, U. Kaiser, R. Sabatowski. Pain

Clinic, University of Dresden, Dresden, Germany

Background: Chronic headache (CH) is a prevalent medical

problem, often complicated by occupational or psychological

cofactors. Efficacy of multimodal treatment approaches (MT)

could be demonstrated for short- and intermediate-term outcome.

However there is only limited evidence of long-term efficacy. Our

prospective study analyses the 1 years catamnesis of CH-patients

treated with MT in a day clinic setting.

Methods: Standardized MT for 4 weeks initially followed by an

additional week 3 months later. Assessments of quality of life (SF-

36), pain (NRS), pain disability (PDI), anxiety/depression (HADS-D)

and coping strategies (CSQ) at the beginning of the treatment (T1),

after 1 (T2), 3 (T3), 6 (T4) and 12 (T5) months. Only T5 data will be

presented. A p≤0.05 was regarded as statistically significant. Effect

sizes (ES) were calculated.

Results: Questionnaires at T5 were available from 30 patients

(migraine 60%; tension headache 23%, miscellaneous 17%;

treatment period 2006–2007; mean age 50; gender: 83% female).

All parameters tested revealed a statistical significant improvement

(T5 vs. T1). In the CSQ the most remarkably improvement was

achieved in catastrophizing (T1-T5: p < 0.001, ES 0.88). Average pain

intensity scores decreased significantly (T1-T5: p < 0.001, ES 0.84) as

well. At T5 the bodily component score of the SF-36 was improved

with a medium effect size (p < 0.001, ES 0.62).

Conclusions: The results suggest that there is a long-term benefit,

even one year after MT, in patients suffering from CH.